Teva- Pharmaceutical Industries 

€15.85
373
+€0.05+0.32% Friday 13:36

Statistik

Harga Tertinggi Hari Ini
16
Harga Terendah Hari Ini
14.8
52M Tinggi
-
52M Rendah
-
Volume
1,479
Rata-Rata Volume
-
Kap Pasar
17.73B
Rasio P/E
-
Hasil Dividen
-
Dividen
-

Mendatang

Dividen

0%Hasil Dividen
Pertumbuhan 10T
T/A
Pertumbuhan 5T
T/A
Pertumbuhan 3T
T/A
Pertumbuhan 1T
T/A

Pendapatan

6NovDiharapkan
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Berikutnya
0.4
0.6
0.8
1
EPS yang Diharapkan
0.66
EPS Aktual
T/A

Orang Juga Mengikuti

Daftar ini didasarkan pada daftar pantauan orang-orang di Stock Events yang mengikuti TEV.F. Ini bukan rekomendasi investasi.

Peserta

Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.

Tentang

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Show more...
CEO
Mr. Richard D. Francis
Karyawan
35001
Negara
US
ISIN
US8816242098
WKN
000883035

Daftar